^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS G12

    i
    Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    1d
    A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=175, Active, not recruiting, Astellas Pharma Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    2d
    Metatypic Carcinoma of the Pancreas: Delineation of a Clinicopathologically Distinct Entity, Characterized by Centrally Necrotic Demarcated High-Grade Carcinoma With Divergent Patterns, Basal Immunophenotype, and Altered Molecular Profile. (PubMed, Am J Surg Pathol)
    It is the first pancreatic carcinoma type in which a basal molecular phenotype can be indicated clinically by both imaging and histopathology, with major potential management implications (as it is also enriched in actionable targets like ARID1A). Recognition of this category is critical for cancer research, as it offers an invaluable group to study plasticity, stroma versatility, necrosis mechanisms, and the basal type in pancreatic cancer.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • SMAD4 (SMAD family member 4) • GATA6 (GATA Binding Protein 6) • TP63 (Tumor protein 63)
    |
    TP53 mutation • KRAS mutation • KRAS G12D • KRAS G12
    3d
    KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, Corregene Biotechnology Co., Ltd | Not yet recruiting --> Active, not recruiting | N=18 --> 8
    Enrollment closed • Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12
    |
    cyclophosphamide • fludarabine IV
    3d
    Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C. (PubMed, Nat Commun)
    Furthermore, both inhibitor classes show similar cellular efficacy in the presence of growth factors that drive KRAS, wt NRAS, and wt HRAS to the active state. These data provide the first detailed account of targeting both the active and inactive states of KRAS G12C and highlight the absence of a mechanistic advantage in contexts dependent on prolonged target inhibition.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS G12C • KRAS G12 • NRAS wild-type
    4d
    HRS-4642 combined with Nimotuzumab in the treatment of recurrent or metastatic pancreatic ductal adenocarcinoma with KRAS G12D mutation that has failed systemic therapy (ChiCTR2500098420)
    P1/2, N=20, Recruiting, West China Hospital,Sichuan University; West China Hospital,Sichuan University | N=10 --> 20
    Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase) • CA 19-9 (Cancer antigen 19-9)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    TheraCIM (nimotuzumab) • HRS-4642
    4d
    A study to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of SapK573 tumor vaccine injection in patients with advanced solid tumors with KRAS mutations (ChiCTR2500113691)
    P=N/A, N=12, Not yet recruiting, Cancer Hospital of Chinese Academy of Medical Sciences; Cancer Hospital of Chinese Academy of Medical Sciences
    New trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12 • KRAS G13
    4d
    HRS-4642-206: Phase IB/II clinical study of the safety, tolerability and efficacy of HRS-4642 in combination with other anti-tumor drugs in subjects with solid tumors (ChiCTR2500115250)
    P1/2, N=60, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    AiRuiLi (adebrelimab) • HRS-4642
    4d
    An open-label, multicenter Phase I clinical study to evaluate the safety, tolerability and immunogenicity of RGL-232 in patients with advanced malignant solid tumors carrying KRAS mutations (ChiCTR2500115334)
    P1, N=32, Not yet recruiting, Zhejiang Cancer Hospital; Shanghai Ruihongdi Pharmaceutical Co., LTD
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12 • KRAS G13
    4d
    Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-B01D1 for Injection in Patients with Locally Advanced or Metastatic Solid Tumors (ChiCTR2500113663)
    P1, N=500, Not yet recruiting, Sun Yat-sen University Cancer Center; Sichuan Baili Pharmaceutical Co., Ltd.
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • RET fusion • MET exon 14 mutation • ALK fusion • EGFR L861Q • RET mutation • ROS1 fusion • EGFR G719X • MET mutation • EGFR S768I • KRAS G12 • NTRK fusion
    |
    izalontamab brengitecan (BL-B01D1)
    4d
    A single-arm phase II exploratory study of glutamine combined with oxaliplatin, capecitabine (XELOX) and bevacizumab as the first-line treatment for advanced colorectal cancer with KRAS G12D gene mutation (ChiCTR2500108082)
    P2, N=20, Recruiting, The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS mutation • BRAF mutation • KRAS G12D • BRAF wild-type • KRAS G12
    |
    Avastin (bevacizumab) • capecitabine • oxaliplatin
    4d
    Glutamine combined with albumin-bound paclitaxel and gemcitabine in the treatment of advanced pancreatic cancer with KRAS G12D mutation (ChiCTR2500103114)
    P2, N=40, Recruiting, The Second Affiliated Hospital Zhejiang University School of Medicine; The Second Affiliated Hospital Zhejiang University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    gemcitabine • albumin-bound paclitaxel
    4d
    The Stmn1-lineage contributes to acinar regeneration but not to neoplasia upon oncogenic Kras expression. (PubMed, Cell Mol Gastroenterol Hepatol)
    Our findings establish the Stmn1-lineage as a pivotal subpopulation for acinar regeneration. The ability of these cells to restore acinar tissue in an ADM-independent manner distinguishes them as a critical regenerative population. This study presents a new paradigm for acinar regeneration and repair in the context of pancreatitis and neoplasia.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • STMN1 (Stathmin 1)
    |
    KRAS G12D • KRAS G12